



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/052,482	11/08/2001	David W. Morris	529452500124	2512

7590 03/30/2005

Shantanu Basu  
Morrison & Foerster LLP  
755 Page Mill Road  
Palo Alto, CA 94304-1018

EXAMINER

HARRIS, ALANA M

ART UNIT	PAPER NUMBER
----------	--------------

1642

DATE MAILED: 03/30/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

Application No.

10/052,482

Applicant(s)

MORRIS ET AL.

Examiner

Alana M. Harris, Ph.D.

Art Unit

1642

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☐ Responsive to communication(s) filed on \_\_\_\_.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 1-19 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) \_\_\_\_ is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_ is/are objected to.
- 8) ☒ Claim(s) 1-19 are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. ____. |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                   | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date ____. | 6) <input type="checkbox"/> Other: ____.  |

***Election/Restrictions***

1. Each of the following Groups consists of three sequences inclusive of *either* mouse genomic, mRNA and coding sequences or human genomic, mRNA and coding sequences. With the *election of one group* the three sequences contained within the group will be searched. See the attached listing of the Tables, which further identify each Group.
2. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - 1-79. Claims 1-4, drawn to a recombinant nucleic acid listed in Tables 1-40 consisting of sequences, SEQ ID NO: 1-237 and the expression vector and host cell, which the said nucleic acid is contained, respectively, classified in class 536, subclass 23.5.
  - 80-158. Claim 5, drawn to a recombinant protein encoded by one of the seventy-nine coding sequences listed in Tables 1-40, respectively, classified in class 530, subclass 350.
  - 159-237. Claims 6 and 7, drawn to a method of screening drug candidates comprising providing a cell that expresses a carcinoma associated (CA) gene comprising a nucleic acid sequence listed in Tables 1-40 and adding a drug candidate to said cell and determining the level of CA gene expression, respectively, classified in class 435, subclass 6.

- 238-316. Claims 8 and 9, drawn to a method of screening for a bioactive agent capable of binding and modulating the activity of an CA protein (CAP) encoded by one of the seventy-nine coding sequences comprising combining said CAP and a candidate bioactive agent and determining bioactivity of said CAP, respectively, classified in class 435, subclass 7.1.
- 317-395. Claims 10 and 11, drawn to a method of evaluating the effect of a candidate carcinoma drug comprising administering said drug to a patient, removing a cell sample and determining alterations in the expression or activation of a gene comprising a nucleic acid sequence consisting of a sequence outlined in Tables 1-40, respectively, classified in class 436, subclass 63.
- 396-474. Claim 12, drawn to a method for inhibiting the activity of a CAP encoded by one of the nucleic acid sequences outlined in Tables 1-40, respectively, classified in class 435, subclass 7.1.
- 475-553. Claims 13 and 14, drawn to a method of treating carcinomas comprising administering to a patient an inhibitor of an CAP, wherein the CAP is encoded by one of the nucleic acid sequences outlined in Tables 1-40, respectively, classified in class 424, subclass 130.1.
- 554-632. Claims 15 and 16, drawn to an antibody, which specifically binds to a protein encoded by one of the nucleic acid coding sequences outlined in Tables 1-40, respectively, classified in class 530, subclass 387.1.

633-711. Claim 17, drawn to a biochip comprising one or more nucleic acid segments selected from the group consisting of one of the nucleic acid of the sequences outlined in Tables 1-40, respectively, classified in class 536, subclass 23.1.

712-790. Claim 18, drawn to a method of diagnosing carcinoma by sequencing at least CA gene, respectively, classified in class 536, subclass 174.

791-869. Claim 19, drawn to a method of determining CA gene copy number comprising adding an CA gene probe comprising a sequence of Tables 1-40 to a sample of genomic DNA from an individual and implementing hybridization, respectively, classified in class 435, subclass 7.92.

2. The inventions are distinct, each from the other because of the following reasons:  
Groups 1-158 and 554-711 are structurally and functionally different products, which are made by different methods and have different uses.

The methods of Groups 159-475 and 712-869 differ in the method objectives, method steps and parameters and in the reagents used.

The examination of all groups would require different searches in the U.S. Patent Shoes and the scientific literature and would require the consideration of different patentability issues.

Inventions 159-316, 396-474, 712-869 and 317-395, 475-553 are unrelated.  
Inventions are unrelated if it can be shown that they are not disclosed as capable of use

Art Unit: 1642

together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the *in vitro* methods of Inventions 159-316, 396-474, 712-869 are distinct and independent from the *in vivo* methods of Inventions 317-395, 475-553 and are not useable or searchable together.

Inventions 633-711 are related to Groups 712-869 as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the biochip products of Group 633-711 could be used in any of the methods of Groups 712-869.

Inventions 159-395, 475-553 are unrelated to Inventions 633-711. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the methods Groups of 159-395, 475-553 cannot use the biochips of the Groups 633-711, thus not useable nor searchable together.

3. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Art Unit: 1642

4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

5. Further clarification of each Group is presented in the following sheets.


Art Unit: 1642

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Alana M. Harris, Ph.D. whose telephone number is (571)272-0831. The examiner works a flexible schedule, however she can normally be reached between the hours of 6:30 am to 5:30 pm, with alternate Fridays off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Siew can be reached on (571) 272-0787. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Alana M. Harris, Ph.D.  
25 March 2005

  
**ALANA M. HARRIS, PH.D.**  
**PRIMARY EXAMINER**  
3/28/2005